Drugs / PEG-BCT-100
PEG-BCT-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02285101 | Nov 2014 → Feb 2019 | melanoma, prostate adenocarcinoma | Bio-Cancer Treatment International Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02899286 | Sep 2016 → Sep 2019 | acute myeloid leukemia | Bio-Cancer Treatment International Limited | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-BCT-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02285101 ↗ |
| Known as | BCT-100 | “treated with 2 mg/kg intravenously, weekly pegylated recombinant arginase (BCT-100).” PMID 29776373 ↗ May 2018 |
| Known as | PEGylated recombinant human arginase | “PEG-BCT-100 (PEGylated recombinant human arginase)” NCT02899286 ↗ |
| Known as | Recombinant Human Arginase 1 | “A Phase II Open-label Study of the Efficacy and Safety of Recombinant Human Arginase 1 (PEG-BCT-100) in Patients With Relapsed or Refractory Acute Myeloid Leukemia” NCT02899286 ↗ |
| Modality | Protein / enzyme biologic | “PEG-BCT-100 is an enzyme that degrades arginine and is an investigational drug.” NCT02285101 ↗ |
| Route | Intravenous | “Eligible patients will receive intravenous (IV) infusion of PEG-BCT-100 weekly” NCT02899286 ↗ |